4475 Wayburne Drive
Unit 210
Burnaby, BC V5G 4X4
Canada
https://filament.health
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 13
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Benjamin Lightburn | Co-Founder, CEO & Chairman | 130.12k | N/A | 1987 |
Andry Tjahyana | VP of Business Development | 141.28k | N/A | N/A |
Mr. Jonathan Conlin | Corporate Secretary & Director | N/A | N/A | 1985 |
Mr. Steven Nguyen CPA | Interim Chief Financial Officer | N/A | N/A | 1995 |
Ms. Lisa Ranken | Chief Operating Officer | N/A | N/A | 1984 |
Mr. Ryan Moss | Chief Science Officer | N/A | N/A | N/A |
Ms. Anna Cordon | Vice President of Marketing & Communications | N/A | N/A | N/A |
Mr. Jeff Fellows | Head of Regulatory | N/A | N/A | N/A |
Sara Burke B.A., M.B.A. | Head of Global Partnerships | N/A | N/A | N/A |
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.
Filament Health Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.